MEG3 and neoplasm: By positioning MEG3 as a mediator of drug sensitivity, our study not only consolidates its role in tumor biology but also suggests that the efficacy of both nanotechnology-based and conventional therapies is tightly interwoven with the lncRNA regulatory landscape.